ADENO-ASSOCIATED VIRUS VECTOR DELIVERY FOR MUSCULAR DYSTROPHIES
The disclosure provides method of treating muscular dystrophy in a subject in need comprising administering a gene therapy vector, such as adeno-associated virus (AAV) vector, expressing a miniaturized human micro-dystrophin gene in combination with a step of suppressing the subject's immune sy...
Saved in:
| Main Authors | , , , , |
|---|---|
| Format | Patent |
| Language | English Spanish |
| Published |
03.04.2023
|
| Subjects | |
| Online Access | Get full text |
Cover
| Summary: | The disclosure provides method of treating muscular dystrophy in a subject in need comprising administering a gene therapy vector, such as adeno-associated virus (AAV) vector, expressing a miniaturized human micro-dystrophin gene in combination with a step of suppressing the subject's immune system.
La descripción proporciona un método para tratar la distrofia muscular, en un sujeto que lo necesita, que comprende la administración de un vector de terapia génica, como un vector de virus adenoasociado (AAV), que expresa un gen de microdistrofina humana miniaturizada en combinación con una etapa de supresión del sistema inmunitario del sujeto. |
|---|---|
| Bibliography: | Application Number: MX20220016332 |